Genmab: Darzalex Meets Main Endpoint in Light-Chain Amyloidosis Study
May 28 2020 - 2:41PM
Dow Jones News
By Colin Kellaher
Genmab A/S on Thursday said a phase 3 study of the cancer drug
Darzalex met its primary endpoint in the most common type of
amyloidosis, a rare disease that occurs when an abnormal protein
called amyloid builds up in a body's tissues and organs.
The Copenhagen biotechnology company said subcutaneous Darzalex
in combination with cyclophosphamide, bortezomib and dexamethasone
for patients with newly diagnosed light-chain amyloidosis met the
primary endpoint of percentage of patients with hematologic
complete response.
Genmab said the study was conducted by Johnson & Johnson's
Janssen Biotech Inc. unit, which has an exclusive license to
develop, manufacture and commercialize Darzalex under an August
2012 agreement.
Genmab said Janssen will discuss with health authorities the
potential for a regulatory submission for the indication, adding
that there are currently no approved treatments for the progressive
disease.
Darzalex is already approved in several indications in multiple
myeloma, a cancer that forms in a type of white blood cells called
plasma cells and causes cancer cells to accumulate in the bone
marrow.
U.S.-listed shares of Genmab were recently up 4.6% to $31.06.
Johnson & Johnson shares gained 2.1% to $147.90.
Write to Colin Kellaher at colin.kellaher@wsj.com
(END) Dow Jones Newswires
May 28, 2020 14:26 ET (18:26 GMT)
Copyright (c) 2020 Dow Jones & Company, Inc.
Johnson and Johnson (NYSE:JNJ)
Historical Stock Chart
From Mar 2024 to Apr 2024
Johnson and Johnson (NYSE:JNJ)
Historical Stock Chart
From Apr 2023 to Apr 2024